Medical cannabis patients reported mixed effects from recreational legalization
Medical cannabis patients reported that recreational legalization reduced stress and legal concerns and improved product quality, but increased prices and some reported accessibility issues, while social stigma notably decreased.
Quick Facts
What This Study Found
Quantitative analysis showed legalization decreased stress and legal concerns, increased perceived product quality and availability, but also increased prices. Qualitative analysis largely aligned but revealed divergent views on price and availability. Mixed-methods analysis found legalization also reduced social stigma.
Key Numbers
505 medical cannabis patients surveyed. 24 US states have legalized adult use. Patients reported decreased stress, increased product quality, but higher prices. Social stigma notably reduced.
How They Did This
Online survey of 505 medical cannabis patients in US states with adult-use laws. Forced-choice and open-ended questions analyzed with quantitative, qualitative (thematic), and mixed-methods approaches.
Why This Research Matters
As more states transition from medical-only to adult-use, understanding the medical patient experience helps policymakers design transitions that protect therapeutic access.
The Bigger Picture
The reduction in social stigma may be one of the most important but least discussed effects of recreational legalization for medical patients. Feeling less judged for using a medication can improve treatment adherence and quality of life.
What This Study Doesn't Tell Us
Convenience sample may overrepresent engaged patients. Self-selected participants in legal states. Cannot compare to patients in medical-only states. Online survey excludes some populations.
Questions This Raises
- ?How can states maintain affordable medical access when recreational markets drive prices?
- ?Do patients leaving medical programs lose important clinical guidance?
Trust & Context
- Key Stat:
- Reduced stigma but higher prices
- Evidence Grade:
- Convenience sample survey with mixed-methods analysis provides nuanced insights but limited generalizability.
- Study Age:
- 2024 survey of medical cannabis patients in adult-use states
- Original Title:
- Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients.
- Published In:
- Journal of psychoactive drugs, 1-10 (2024)
- Authors:
- Boehnke, Kevin F(22), Kruger, Daniel J(9), Cuttler, Carrie(13), Doucette, Mitchell L, Wilson-Poe, Adrianne R
- Database ID:
- RTHC-05143
Evidence Hierarchy
Frequently Asked Questions
How does recreational legalization affect medical patients?
Patients reported reduced legal stress and social stigma, better product quality, but higher prices. Some experienced improved accessibility while others faced challenges as medical programs merged into recreational markets.
Did patients experience more stigma before legalization?
Yes. Both quantitative and qualitative data showed recreational legalization notably reduced the social stigma medical patients experienced around their cannabis use.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-05143APA
Boehnke, Kevin F; Kruger, Daniel J; Cuttler, Carrie; Doucette, Mitchell L; Wilson-Poe, Adrianne R. (2024). Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients.. Journal of psychoactive drugs, 1-10. https://doi.org/10.1080/02791072.2024.2430608
MLA
Boehnke, Kevin F, et al. "Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients.." Journal of psychoactive drugs, 2024. https://doi.org/10.1080/02791072.2024.2430608
RethinkTHC
RethinkTHC Research Database. "Highs and Lows: A Mixed-Methods Analysis of the Impact of Ad..." RTHC-05143. Retrieved from https://rethinkthc.com/research/boehnke-2024-highs-and-lows-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.